Predicting the Risk of Huntington's Disease with Multiple Longitudinal Biomarkers

Overview

Journal J Huntingtons Dis

Publisher Sage Publications

Date 2019 Jul 1

PMID 31256145

Authors

Fan Li

Kan Li

Cai Li

Sheng Luo

Affiliations

Soon will be listed here.

Abstract

Background: Huntington's disease (HD) has gradually become a public health threat, and there is a growing interest in developing prognostic models to predict the time for HD diagnosis.

Objective: This study aims to develop a novel prognostic model that leverages multiple longitudinal biomarkers to inform the risk of HD.

Methods: The multivariate functional principal component analysis was used to summarize the essential information from multiple longitudinal markers and to obtain a set of prognostic scores. The prognostic scores were used as predictors in a Cox model to predict the right-censored time to diagnosis. We used cross-validation to determine the best model in PREDICT-HD (n = 1,039) and ENROLL-HD (n = 1,776); external validation was carried out in ENROLL-HD.

Results: We considered six commonly measured longitudinal biomarkers in PREDICT-HD and ENROLL-HD (Total Motor Score, Symbol Digit Modalities Test, Stroop Word Test, Stroop Color Test, Stroop Interference Test, and Total Functional Capacity). The prognostic model utilizing these longitudinal biomarkers significantly improved the predictive performance over the model with baseline biomarker information. A new prognostic index was computed using the proposed model, and can be dynamically updated over time as new biomarker measurements become available.

Conclusion: Longitudinal measurements of commonly measured clinical biomarkers substantially improve the risk prediction of Huntington's disease diagnosis. Calculation of the prognostic index informs the patient's risk category and facilitates patient selection in future clinical trials.

References

Gerds T, Schumacher M . Consistent estimation of the expected Brier score in general survival models with right-censored event times. Biom J. 2007; 48(6):1029-40. DOI: 10.1002/bimj.200610301. View

Paulsen J, Hayden M, Stout J, Langbehn D, Aylward E, Ross C . Preparing for preventive clinical trials: the Predict-HD study. Arch Neurol. 2006; 63(6):883-90. DOI: 10.1001/archneur.63.6.883. View

Garcia T, Wang Y, Shoulson I, Paulsen J, Marder K . Disease Progression in Huntington Disease: An Analysis of Multiple Longitudinal Outcomes. J Huntingtons Dis. 2018; 7(4):337-344. PMC: 9012322. DOI: 10.3233/JHD-180297. View

Royston P, Altman D . External validation of a Cox prognostic model: principles and methods. BMC Med Res Methodol. 2013; 13:33. PMC: 3667097. DOI: 10.1186/1471-2288-13-33. View

Ibrahim J, Chu H, Chen L . Basic concepts and methods for joint models of longitudinal and survival data. J Clin Oncol. 2010; 28(16):2796-801. PMC: 4503792. DOI: 10.1200/JCO.2009.25.0654. View

Blanche P, Dartigues J, Jacqmin-Gadda H . Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks. Stat Med. 2013; 32(30):5381-97. DOI: 10.1002/sim.5958. View

Li K, Furr-Stimming E, Paulsen J, Luo S . Dynamic Prediction of Motor Diagnosis in Huntington's Disease Using a Joint Modeling Approach. J Huntingtons Dis. 2017; 6(2):127-137. PMC: 5505650. DOI: 10.3233/JHD-170236. View

Paulsen J, Long J, Ross C, Harrington D, Erwin C, Williams J . Prediction of manifest Huntington's disease with clinical and imaging measures: a prospective observational study. Lancet Neurol. 2014; 13(12):1193-201. PMC: 4373455. DOI: 10.1016/S1474-4422(14)70238-8. View

Long J, Mills J, Leavitt B, Durr A, Roos R, Stout J . Survival End Points for Huntington Disease Trials Prior to a Motor Diagnosis. JAMA Neurol. 2017; 74(11):1352-1360. PMC: 5710578. DOI: 10.1001/jamaneurol.2017.2107. View

10.

Long J, Mills J . Joint modeling of multivariate longitudinal data and survival data in several observational studies of Huntington's disease. BMC Med Res Methodol. 2018; 18(1):138. PMC: 6240282. DOI: 10.1186/s12874-018-0592-9. View

11.

Debray T, Vergouwe Y, Koffijberg H, Nieboer D, Steyerberg E, Moons K . A new framework to enhance the interpretation of external validation studies of clinical prediction models. J Clin Epidemiol. 2014; 68(3):279-89. DOI: 10.1016/j.jclinepi.2014.06.018. View

12.

Long J, Paulsen J . Multivariate prediction of motor diagnosis in Huntington's disease: 12 years of PREDICT-HD. Mov Disord. 2015; 30(12):1664-72. PMC: 4795466. DOI: 10.1002/mds.26364. View

13.

Langbehn D, Hayden M, Paulsen J . CAG-repeat length and the age of onset in Huntington disease (HD): a review and validation study of statistical approaches. Am J Med Genet B Neuropsychiatr Genet. 2009; 153B(2):397-408. PMC: 3048807. DOI: 10.1002/ajmg.b.30992. View

14.

Li K, OBrien R, Lutz M, Luo S . A prognostic model of Alzheimer's disease relying on multiple longitudinal measures and time-to-event data. Alzheimers Dement. 2018; 14(5):644-651. PMC: 5938096. DOI: 10.1016/j.jalz.2017.11.004. View

15.

. Unified Huntington's Disease Rating Scale: reliability and consistency. Huntington Study Group. Mov Disord. 1996; 11(2):136-42. DOI: 10.1002/mds.870110204. View

16.

Xiao L, Li C, Checkley W, Crainiceanu C . Fast covariance estimation for sparse functional data. Stat Comput. 2018; 28(3):511-522. PMC: 5807553. DOI: 10.1007/s11222-017-9744-8. View

17.

Mogensen U, Ishwaran H, Gerds T . Evaluating Random Forests for Survival Analysis using Prediction Error Curves. J Stat Softw. 2014; 50(11):1-23. PMC: 4194196. DOI: 10.18637/jss.v050.i11. View

18.

. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell. 1993; 72(6):971-83. DOI: 10.1016/0092-8674(93)90585-e. View

19.

Paulsen J, Langbehn D, Stout J, Aylward E, Ross C, Nance M . Detection of Huntington's disease decades before diagnosis: the Predict-HD study. J Neurol Neurosurg Psychiatry. 2007; 79(8):874-80. PMC: 2569211. DOI: 10.1136/jnnp.2007.128728. View

20.

Zhang Y, Long J, Mills J, Warner J, Lu W, Paulsen J . Indexing disease progression at study entry with individuals at-risk for Huntington disease. Am J Med Genet B Neuropsychiatr Genet. 2011; 156B(7):751-63. PMC: 3174494. DOI: 10.1002/ajmg.b.31232. View